Cimzia (Certolizumab pegol) for Psoriasis

Overview
Cimzia is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for treating active psoriatic arthritis in adults 18 years and older. Cimzia may be prescribed alone or with methotrexate. Cimzia is also known by its drug name, certolizumab pegol.

Cimzia is a biologic drug composed of a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Cimzia is believed to work by inhibiting tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks.

How do I take it?
Cimzia is administered by subcutaneous injection every two to four weeks.

Cimzia comes in prefilled syringes and vials.

Side effects
The FDA-approved label for Cimzia lists common side effects including upper respiratory infections, urinary tract infections, and rash.

Rare but serious side effects listed for Cimzia can include life-threatening infections, heart failure, hypersensitivity reactions, hepatitis B reinfection, neurologic reactions, lupus-like syndrome, and increased risk of developing certain types of cancer such as lymphoma.

For more information about this treatment, visit:

Cimzia — UCB
https://www.cimzia.com